TLR7 and neoplasm: Combining the nanoadjuvants with OVA peptide or tumor cell lysate triggered a robust antigen‐specific immune response and reduced tumor growth and metastasis.105 Researchers also developed pyruvate dehydrogenase E2 protein nanoparticles for codelivery of CpG and gp100.106 Chen et al. integrated TLR7 agonist (imiquimod) into PLGA nanoparticles and coencapsulated photothermal agent (indocyanine green) for combination therapy.